CAJ | 학술논문

目的：观察疏肝解郁法联合化疗治疗乳腺癌的临床疗效。方法：将乳腺癌患者56例随机分为2组，治疗组在DA方案化疗基础上加用疏肝解郁代表方柴胡疏肝散加减治疗，对照组采用常规DA方案化疗。3周为1个疗程，治疗2个疗程后以Karnorsky评分法为标准，比较2组患者生活质量、不良反应及预后。结果：Karnorsky评分治疗组高于对照组，差异有统计学意义(P＜0.05)；化疗引起的不良反应方面治疗组低于对照组，差异有统计学意义(P＜0.05)；治疗组白细胞、红细胞、血小板减少以及血红蛋白降低的发生率均显著低于对照组，差异具有统计学意义(P＜0.05)；2组患者治疗后12、24、36个月的生存率比较差异无统计学意义(P＞0.05)。结论：疏肝解郁法联合DA方案治疗乳腺癌能提高乳腺癌患者化疗后的生活质量，减轻化疗所致的毒副反应。
목적：관찰소간해욱법연합화료치료유선암적림상료효。방법：장유선암환자56례수궤분위2조，치료조재DA방안화료기출상가용소간해욱대표방시호소간산가감치료，대조조채용상규DA방안화료。3주위1개료정，치료2개료정후이Karnorsky평분법위표준，비교2조환자생활질량、불량반응급예후。결과：Karnorsky평분치료조고우대조조，차이유통계학의의(P＜0.05)；화료인기적불량반응방면치료조저우대조조，차이유통계학의의(P＜0.05)；치료조백세포、홍세포、혈소판감소이급혈홍단백강저적발생솔균현저저우대조조，차이구유통계학의의(P＜0.05)；2조환자치료후12、24、36개월적생존솔비교차이무통계학의의(P＞0.05)。결론：소간해욱법연합DA방안치료유선암능제고유선암환자화료후적생활질량，감경화료소치적독부반응。
Objective: To observe therapeutic effects of liver-soothing stagnation-relieving method and chemotherapy in treating breast cancer. Methods:Fifty-six patients were randomized into two groups. The treatment group took modified ChaiHu ShuGan powder on the foundation of DA regimen, and the control group were adminis-tered with conventional DA regimen. Three weeks were one course of the treatment, life quality, adverse reaction and the prognosis of the patients in both groups were compared after two courses of the treatment according to Karnorsky scaling method. Results:Karnorsky scale of the treatment group was higher than that of the control group, the difference showed statistical meaning (P<0.05); the treatment group was lower than the control group in chemotherapy-induced adverse reaction, the difference demonstrated statistical meaning (P<0.05);it was lower than the control group obviously in the incidences of white blood cells, red blood cells, platelet and hemoglobin, the dif-ference showed statistical meaning (P<0.05);the difference had statistical meaning in the comparison of 12, 24 and 36 months survival rate after treating(P>0.05). Conclusion:Liver-soothing stagnation-relieving method and DA reg-imen in treating breast cancer could raise life quality of the patients after breast cancer and alleviate chemothera-py-induced toxicity.